Two-second acquisition
comfortable for patients
Track diseases at the microscopic scale in the retina
"In follow-up examinations of AMD patients, the rtx1 enabled detecting the progression of atrophic lesions over a timescale of weeks, instead of months with conventional imaging."
Prof. Paques. Quinze-Vingts National Hospital, June 2020, Paris, France
"AO technology will likely contribute to faster and more cost effective drug development for the treatment of eye diseases."
Lin et al.
Invest Opth Vis Sc 2019, 60:4520-4531
"Adaptive optics (AO) ophthalmoscopy is now an accessible tool to visualize photoreceptors in the human living retina."
Cristescu et al.
Rom J Ophthalmol. 2019, 63:153-160.
"The rtx1 allowed us to directly observe stem-cell-derived RPE cells after their transplantation in a patient’s retina. We could verify that the mosaic arrangement of these cells was similar to that of natural RPE cells, and stable over time."
Dr. Takagi. Kobe City Eye Center, July 2019, Kobe, Japan
"Direct assessment of photoreceptors in RP patients by high-resolution imaging technologies is crucial for the future development of RP therapeutics."
Lin et al.
Invest Opth Vis Sc 2019, 60:4520-4531
"Several studies of human retinal photoreceptors in diabetic patients using Imagine Eyes’ AO retinal camera have been achieved."
Cristescu et al.
Rom J Ophthalmol. 2019, 63:153-160.
"The rtx1 demonstrates that, unlike the common belief, performing AO retinal imaging can be as easy as standard retinal imaging."
Prof. Paques.
Quinze-Vingt National Hospital, July 2018, Paris, France
"We, for the first time, visualized longitudinal changes during the recovery of cone photoreceptors in the eyes of VKH patients."
Nakamura et al.
Graefes Arch Clin Exp Ophthalmol 2018, 256:387-394
"The image resolution achieved by this technology is superior to that of any other current diagnostic tool."
Zaleska-Zmijewska et al.
Journal of Diabetes Research 2017, article ID 4174292
"Adaptive optics retinal imaging provided non-invasive and sensitive information on the pathologic disruption of the cone mosaic."
Ziccardi et al.
American J Ophthalmol 2015, 160:301-312
"Adaptive optics retinal imaging provided non-invasive and sensitive information on the pathological disruption of the cone mosaic, even in the absence of subjective (visual loss) or objective (diagnostic imaging) abnormalities."
Ziccardi et al.
American Journal of Ophthalmology 2015,160:301–312.e6.
"In all patients, AO images showed dark elements that were smaller than what could be resolved by fundus imaging and OCT."
Bek.
Acta Ophthalmologica 2014, 92:753-758
Fast follow-up workflow
with micrometer precision
Cellular biomarkers
quantify small retinal changes
Over 150 publications
in a wide range of pathologies
Tracking microscopic progression/regression
By design, the rtx1 delivers images that are free from motion distortion. Building on this advantage, its software enables capturing the same retinal region through different visits, and automatically aligns follow-up images. This allows tracking minute changes in a group of cells, a vessel section, or a lesion over time.
Links & Downloads
Specifications
| Imaging type | En face reflectance imaging |
| Detection type | Low-noise CCD camera |
| Illumination | Near infrared LED, 850nm |
| Exposure time | < 10 ms |
| Imaging field of view 1 | 4° x 4° |
| Fixation stimulation range | H ± 14.5° / V ± 10° |
| Camera pixel pitch on the fundus 1 | 1.1 µm |
| Optical resolution on the fundus 1, 2 | 250 line pairs per millimeter (lppmm) |
| Adaptive optics control | Fully automated, resistant to blinking and movement |
| Depth focussing range 1 | 1600 µm |
| Pupil diameter | ≥ 4 mm |
| Refractive error compensation | -12 to +6 D |
| Total footprint (WxDxH) | 137x53x132-162 cm |
1 Some specifications are dependent on several factors including but not limited to: ocular biometry, pupil diameter, optical defects, ocular media transparency.
2 The system can image line pairs of 2 µm in line width.
rtx1 is a certified medical device of class IIa in the European Union. rtx1 is an approved medical device in Japan and China.
In the USA, rtx1 has not received FDA clearance; it is an investigational device that requires Institutional Review Board (IRB) oversight. For use by trained eyecare professionals only.
AOdetect is an option of the certified rtx1 device in the European Union. In other territories, AOdetect is a separate product for research use only.